Scarica l'app Stockscreener
31.04
1.01%
0.31
Dopo l'orario di chiusura:
31.04
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - Kalkine Media
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA SWOT Analysis: Financial Strength and Growth Potential Revealed in 10-Q Filing - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics grants 451,000 stock options to six new hires - scanx.trade
Damora Therapeutics (DMRA) Edges Higher at $29.37 as Traders Eye Key Resistance at $30.84Fade Trade - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) to Post Earnings on Wednesday - MarketBeat
BlackRock (DMRA holder) reports 3.14M Damora Therapeutics shares in new ownership filing - Stock Titan
DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus
Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target - marketscreener.com
H.C. Wainwright reiterates Damora Therapeutics stock rating on device advantage - Investing.com Canada
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies initiates Damora Therapeutics stock with buy rating By Investing.com - Investing.com Canada
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Sahm
Damora Therapeutics (DMRA) Slips 1.2% as Stock Approaches Key Support at $27.38Low Vol ETF - dars.gov.et
Damora Therapeutics, Inc. Revenue Breakdown – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics (DMRA) AGM 2026 Summary - Quartr
Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
symbol__ Stock Quote Price and Forecast - CNN
DMRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Buy on Damora Therapeutics stock By Investing.com - Investing.com Canada
Damora Therapeutics Completes Cayman Islands Redomestication - TipRanks
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading 7.8% HigherShould You Buy? - MarketBeat
Damora Therapeutics completes redomestication to Cayman Islands By Investing.com - Investing.com Nigeria
Damora Therapeutics completes redomestication to Cayman Islands - Investing.com
Damora Announces Redomestication from Delaware to Cayman Islands - The Manila Times
Damora Will Keep DMRA Ticker Under New Nasdaq CUSIP July 20 - Stock Titan
Damora completes redomestication to Cayman Islands - scanx.trade
Damora Therapeutics Inc. (DMRA) Q1 2026 Earnings: Wider-than-Expected Loss on Pre-Revenue Pipeline Progress - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics (DMRA) Plunges 7.3% as Key Support Levels Come Into FocusStock Analysis - po-news-eg.net
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):